Developer docs
API playgroundTry for free, no card

Search company profiles

Corstasis Therapeutics

Full company profile

uuid0002ect

Namestring
Corstasis Therapeutics
Legal namestring
Corstasis Therapeutics Inc.
Websiteurl
corstasis.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Corstasis Therapeutics is a commercial-stage biopharmaceutical company headquartered in Henderson, Nevada, that develops outpatient therapeutic options for fluid overload associated with congestive heart failure (CHF), hepatic disease, and renal disease. Its core asset, Enbumyst (bumetanide nasal spray) 0.5 mg, is the first and only FDA-approved nasal spray loop diuretic, approved in September 2025 for treating edema in CHF, liver, and kidney disease patients. The company also maintains a development pipeline that includes RSQ-786 (a subcutaneous diuretic delivered via a multidose pen injector), RSQ-789 (a subcutaneous diuretic delivered via a smart infusion system), and RSQ-781 (a veterinary diuretic spray), all investigational.

The company's underlying technology is a nasal drug delivery platform for loop diuretics that exploits the nasal capillary network to bypass first-pass hepatic metabolism, delivering bumetanide directly to systemic circulation to address an absorption limitation of oral loop diuretics in certain patient populations. Corstasis generates revenue through prescription product sales of Enbumyst to healthcare providers and outpatient cardiology networks, with a go-to-market model anchored on channel partnerships with US Heart & Vascular, FillPoint Health, and Cardiovascular Logistics in the United States.

The business model combines direct prescription drug sales with a deal structure inherited from the Esperion Therapeutics acquisition completed in April 2026, which provided $75 million upfront, up to $180 million in milestone payments, and low double-digit royalties to former Corstasis shareholders on worldwide Enbumyst sales. Prior to the acquisition, Corstasis had been funded by an undisclosed strategic investment from Triton Funds in June 2023 and operated with a 1-10 employee structure. The Esperion acquisition expands the commercial reach through the acquirer's established cardiovascular field-sales infrastructure for distribution to cardiology practices, hospitals, and outpatient networks across the United States.

Short descriptiontext

Corstasis Therapeutics is a commercial-stage biopharmaceutical company that developed Enbumyst, the first FDA-approved nasal spray loop diuretic for edema in congestive heart failure, hepatic, and renal disease patients. It was acquired by Esperion Therapeutics in April 2026.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersHenderson, United States
HQ citystring
Henderson
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
nasal drug delivery, loop diuretic therapy, heart failure treatment, biopharmaceutical products, outpatient therapeutics
Industry1 code
PRIMARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Cardiovascular Pharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Enbumyst product sales
TypeOne Time License
Description

Corstasis commercializes Enbumyst (bumetanide nasal spray), the first FDA-approved nasal spray loop diuretic, generating revenue through prescription drug sales to healthcare providers and outpatient care networks. Following the acquisition by Esperion Therapeutics, Corstasis shareholders receive low double-digit royalties on worldwide sales plus potential milestone payments.

finance.yahoo.com
2Milestone payments from acquisition
TypeLicensing Royalties
Description

Under the Esperion acquisition agreement, Corstasis shareholders receive up to $180 million in additional milestone payments tied to regulatory and commercial achievements, on top of the $75 million upfront cash payment.

pulse2.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Enbumyst
Description

ENBUMYST (bumetanide nasal spray) - the first and only FDA-approved nasal spray loop diuretic for treating edema associated with congestive heart failure, liver disease, and kidney disease. Approved by FDA in September 2025.

esperion.com
Core offering1 text field

Corstasis Therapeutics is a commercial-stage biopharmaceutical company that develops and commercializes nasal and subcutaneous formulations of loop diuretics. Its core offering is Enbumyst (bumetanide nasal spray) 0.5 mg, the first FDA-approved nasal spray loop diuretic for outpatient treatment of fluid overload associated with congestive heart failure, liver disease, and kidney disease. The company also has a pipeline of investigational subcutaneous and veterinary diuretic delivery programs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Enbumyst demonstrated bioequivalence to oral and IV forms of bumetanide in clinical trials, proving efficacy in patients without heart failure or heart failure risk factors.
+3 more records
Product overview1 text field

Corstasis Therapeutics is a commercial-stage biopharmaceutical company focused on developing innovative outpatient therapeutic options for patients with fluid overload associated with congestive heart failure (CHF), liver, and kidney disease. The company's core product is Enbumyst (bumetanide nasal spray), an FDA-approved nasal spray loop diuretic that provides self-administered outpatient treatment. Beyond Enbumyst, the company has a pipeline of investigational diuretic products including RSQ-786 (subcutaneous multidose pen injector), RSQ-789 (subcutaneous smart infusion system), and RSQ-781 (veterinary diuretic spray), representing alternative delivery methods for diuretic therapy. The company was acquired by Esperion Therapeutics in 2026 for $75 million upfront plus milestones.

Product and service4 records
1Enbumyst (bumetanide nasal spray) 0.5 mg
CategoryCardiovascular Pharmaceuticals
2RSQ-786 (Subcutaneous Diuretic Multidose Pen Injector)
3RSQ-789 (Subcutaneous Diuretic Smart Infusion System)
CategoryCardiovascular Pharmaceuticals (Investigational)
4RSQ-781 (Veterinary Diuretic Spray)
CategoryVeterinary Pharmaceuticals (Investigational)
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-18
Description

US Heart & Vascular announced a strategic collaboration with FillPoint Health and Corstasis Therapeutics to improve access and adherence to Enbumyst across its national network in the United States. The collaboration aimed to streamline delivery, enhance patient outcomes, and expand access to non-oral diuretic therapy, with nationwide rollout planned by 2026.

2FillPoint Health
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-18
Description

FillPoint Health partnered with US Heart & Vascular and Corstasis Therapeutics to improve access and adherence to Enbumyst across US Heart & Vascular's national network. The collaboration targeted outpatient heart failure care with nationwide rollout planned by 2026.

businesswire.com
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-11-26
Description

Corstasis Therapeutics and Cardiovascular Logistics partnered to support clinical adoption of ENBUMYST for outpatient heart failure care following FDA approval. This partnership was among the first to operationalize nasal-delivered loop diuretics in outpatient cardiology networks in the United States.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

American Regent manufactures and distributes injectable bumetanide and other parenteral loop diuretics in the U.S. It addresses the same CHF and edema patient population as Corstasis, currently via IV/IM administration that Enbumyst aims to displace for outpatient use.

TypeBroad incumbent
Description

Pfizer (including its Hospira injectables business) supplies generic parenteral furosemide, the dominant IV loop diuretic in the U.S. Its broad cardiovascular portfolio and established hospital channel make it a relevant incumbent comparable for an outpatient loop diuretic.

TypeBroad incumbent
Description

Eli Lilly (jointly with Boehringer Ingelheim) markets empagliflozin (Jardiance), which carries HFpEF and HFrEF indications. Lilly's large cardiovascular commercial infrastructure is a relevant benchmark for Enbumyst's go-to-market scale and outpatient-channel reach.

TypeEmerging player
Description

Cytokinetics is developing cardiac myosin modulators (e.g., omecamtiv mecarbil and aficamten) for heart failure. Its focus on novel mechanisms targeting the same CHF population makes it a comparable emerging cardiology franchise.

TypeBroad incumbent
Description

Esperion Therapeutics acquired Corstasis in 2026 and now commercializes Enbumyst through its cardiovascular commercial infrastructure (NEXLETOL/NEXLIZET bempedoic acid franchise). It is comparable as a cardiology-focused pharma company operating around Enbumyst as an outpatient CHF asset.

TypeDirect peer
Description

scPharmaceuticals developed Furoscix, a subcutaneous furosemide on-body infusor for outpatient heart failure decongestion. It is the most direct competitive comparable to Corstasis' outpatient diuretic strategy and serves the same CHF fluid-overload patient population through a similar self-administered approach.

TypeEmerging player
Description

Impel Pharmaceuticals is a developer of nasal drug delivery platforms (e.g., Trudhesa for migraine). Its technology overlap with Corstasis' nasal delivery platform makes it a strategically comparable emerging player, even though its therapeutic focus differs.

TypeEmerging player
Description

Windtree Therapeutics is developing istaroxime and other cardiovascular assets for acute heart failure. Its emerging-player status in the same heart failure drug development category, with novel mechanisms and small headcount, makes it a relevant comparable for early-stage CHF innovators.

TypeEmerging player
Description

BioCardia is developing cardiac delivery platforms (including intramyocardial and subcutaneous delivery systems). Its focus on alternative drug-delivery routes for cardiovascular therapy is comparable to Corstasis' pipeline posture around RSQ-786 and RSQ-789 subcutaneous diuretics.

TypeEmerging player
Description

OptiNose develops and commercializes drug-device combinations based on its proprietary nasal delivery technology (e.g., Xhance). It is a directly comparable technology platform for nasal drug delivery that informs device-formulation strategy for Enbumyst-style products.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Corstasis Therapeutics

Cardiovascular Pharmaceuticalscorstasis.com

Corstasis Therapeutics is a commercial-stage biopharmaceutical company that developed Enbumyst, the first FDA-approved nasal spray loop diuretic for edema in congestive heart failure, hepatic, and renal disease patients. It was acquired by Esperion Therapeutics in April 2026.

What Corstasis Therapeutics does

Corstasis Therapeutics is a commercial-stage biopharmaceutical company headquartered in Henderson, Nevada, that develops outpatient therapeutic options for fluid overload associated with congestive heart failure (CHF), hepatic disease, and renal disease. Its core asset, Enbumyst (bumetanide nasal spray) 0.5 mg, is the first and only FDA-approved nasal spray loop diuretic, approved in September 2025 for treating edema in CHF, liver, and kidney disease patients. The company also maintains a development pipeline that includes RSQ-786 (a subcutaneous diuretic delivered via a multidose pen injector), RSQ-789 (a subcutaneous diuretic delivered via a smart infusion system), and RSQ-781 (a veterinary diuretic spray), all investigational.

The company's underlying technology is a nasal drug delivery platform for loop diuretics that exploits the nasal capillary network to bypass first-pass hepatic metabolism, delivering bumetanide directly to systemic circulation to address an absorption limitation of oral loop diuretics in certain patient populations. Corstasis generates revenue through prescription product sales of Enbumyst to healthcare providers and outpatient cardiology networks, with a go-to-market model anchored on channel partnerships with US Heart & Vascular, FillPoint Health, and Cardiovascular Logistics in the United States.

The business model combines direct prescription drug sales with a deal structure inherited from the Esperion Therapeutics acquisition completed in April 2026, which provided $75 million upfront, up to $180 million in milestone payments, and low double-digit royalties to former Corstasis shareholders on worldwide Enbumyst sales. Prior to the acquisition, Corstasis had been funded by an undisclosed strategic investment from Triton Funds in June 2023 and operated with a 1-10 employee structure. The Esperion acquisition expands the commercial reach through the acquirer's established cardiovascular field-sales infrastructure for distribution to cardiology practices, hospitals, and outpatient networks across the United States.

Corstasis Therapeutics firmographics

Firmographics
Name
Corstasis Therapeutics
Legal name
Corstasis Therapeutics Inc.
Website
https://corstasis.com
Company type
Private
Founded year
2023
Operating status
Acquired
Headcount range
1–10 employees
Short description
Corstasis Therapeutics is a commercial-stage biopharmaceutical company that developed Enbumyst, the first FDA-approved nasal spray loop diuretic for edema in congestive heart failure, hepatic, and renal disease patients. It was acquired by Esperion Therapeutics in April 2026.
Ownership category
akta.pro rank

Corstasis Therapeutics industry classification

Industry
Product category
Cardiovascular Pharmaceuticals
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)

Keywords

  • Nasal drug delivery
  • Loop diuretic therapy
  • Heart failure treatment
  • Biopharmaceutical products
  • Outpatient therapeutics

Where Corstasis Therapeutics is headquartered

Location

Headquarters

HQ city
Henderson
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Corstasis Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. Enbumyst product sales: Corstasis commercializes Enbumyst (bumetanide nasal spray), the first FDA-approved nasal spray loop diuretic, generating revenue through prescription drug sales to healthcare providers and outpatient care networks. Following the acquisition by Esperion Therapeutics, Corstasis shareholders receive low double-digit royalties on worldwide sales plus potential milestone payments.
  2. Milestone payments from acquisition: Under the Esperion acquisition agreement, Corstasis shareholders receive up to $180 million in additional milestone payments tied to regulatory and commercial achievements, on top of the $75 million upfront cash payment.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Corstasis Therapeutics product offering

Product offering

Core offering

Corstasis Therapeutics is a commercial-stage biopharmaceutical company that develops and commercializes nasal and subcutaneous formulations of loop diuretics. Its core offering is Enbumyst (bumetanide nasal spray) 0.5 mg, the first FDA-approved nasal spray loop diuretic for outpatient treatment of fluid overload associated with congestive heart failure, liver disease, and kidney disease. The company also has a pipeline of investigational subcutaneous and veterinary diuretic delivery programs.

Product overview

Corstasis Therapeutics is a commercial-stage biopharmaceutical company focused on developing innovative outpatient therapeutic options for patients with fluid overload associated with congestive heart failure (CHF), liver, and kidney disease. The company's core product is Enbumyst (bumetanide nasal spray), an FDA-approved nasal spray loop diuretic that provides self-administered outpatient treatment. Beyond Enbumyst, the company has a pipeline of investigational diuretic products including RSQ-786 (subcutaneous multidose pen injector), RSQ-789 (subcutaneous smart infusion system), and RSQ-781 (veterinary diuretic spray), representing alternative delivery methods for diuretic therapy. The company was acquired by Esperion Therapeutics in 2026 for $75 million upfront plus milestones.

Differentiator

Problem solved

Functional benefit

Brands

  • Enbumyst: ENBUMYST (bumetanide nasal spray) - the first and only FDA-approved nasal spray loop diuretic for treating edema associated with congestive heart failure, liver disease, and kidney disease. Approved by FDA in September 2025.

Products and services

  • Enbumyst (bumetanide nasal spray) 0.5 mg
  • RSQ-786 (Subcutaneous Diuretic Multidose Pen Injector)
  • RSQ-789 (Subcutaneous Diuretic Smart Infusion System)
  • RSQ-781 (Veterinary Diuretic Spray)

Quantifiable outcome

  • Enbumyst demonstrated bioequivalence to oral and IV forms of bumetanide in clinical trials, proving efficacy in patients without heart failure or heart failure risk factors.
  • +3 more outcomes

Companies that use Corstasis Therapeutics

Customer profile

Segments3 records

Ideal customer profiles2 records

Corstasis Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Corstasis Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered major.

  • US Heart & VascularmajorChannel Partner/ Reseller/ Distributor · 18 December 2025US Heart & Vascular announced a strategic collaboration with FillPoint Health and Corstasis Therapeutics to improve access and adherence to Enbumyst across its national network in the United States. The collaboration aimed to streamline delivery, enhance patient outcomes, and expand access to non-oral diuretic therapy, with nationwide rollout planned by 2026.
  • FillPoint HealthmajorChannel Partner/ Reseller/ Distributor · 18 December 2025FillPoint Health partnered with US Heart & Vascular and Corstasis Therapeutics to improve access and adherence to Enbumyst across US Heart & Vascular's national network. The collaboration targeted outpatient heart failure care with nationwide rollout planned by 2026.
  • Cardiovascular LogisticsmajorChannel Partner/ Reseller/ Distributor · 26 November 2025Corstasis Therapeutics and Cardiovascular Logistics partnered to support clinical adoption of ENBUMYST for outpatient heart failure care following FDA approval. This partnership was among the first to operationalize nasal-delivered loop diuretics in outpatient cardiology networks in the United States.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Corstasis Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • American Regent: American Regent manufactures and distributes injectable bumetanide and other parenteral loop diuretics in the U.S. It addresses the same CHF and edema patient population as Corstasis, currently via IV/IM administration that Enbumyst aims to displace for outpatient use.
  • Pfizer Inc. Pfizer (including its Hospira injectables business) supplies generic parenteral furosemide, the dominant IV loop diuretic in the U.S. Its broad cardiovascular portfolio and established hospital channel make it a relevant incumbent comparable for an outpatient loop diuretic.
  • Eli Lilly and Company: Eli Lilly (jointly with Boehringer Ingelheim) markets empagliflozin (Jardiance), which carries HFpEF and HFrEF indications. Lilly's large cardiovascular commercial infrastructure is a relevant benchmark for Enbumyst's go-to-market scale and outpatient-channel reach.
  • Esperion Therapeutics: Esperion Therapeutics acquired Corstasis in 2026 and now commercializes Enbumyst through its cardiovascular commercial infrastructure (NEXLETOL/NEXLIZET bempedoic acid franchise). It is comparable as a cardiology-focused pharma company operating around Enbumyst as an outpatient CHF asset.

Emerging players

  • Cytokinetics, Inc. Cytokinetics is developing cardiac myosin modulators (e.g., omecamtiv mecarbil and aficamten) for heart failure. Its focus on novel mechanisms targeting the same CHF population makes it a comparable emerging cardiology franchise.
  • Impel Pharmaceuticals: Impel Pharmaceuticals is a developer of nasal drug delivery platforms (e.g., Trudhesa for migraine). Its technology overlap with Corstasis' nasal delivery platform makes it a strategically comparable emerging player, even though its therapeutic focus differs.
  • Windtree Therapeutics: Windtree Therapeutics is developing istaroxime and other cardiovascular assets for acute heart failure. Its emerging-player status in the same heart failure drug development category, with novel mechanisms and small headcount, makes it a relevant comparable for early-stage CHF innovators.
  • BioCardia, Inc. BioCardia is developing cardiac delivery platforms (including intramyocardial and subcutaneous delivery systems). Its focus on alternative drug-delivery routes for cardiovascular therapy is comparable to Corstasis' pipeline posture around RSQ-786 and RSQ-789 subcutaneous diuretics.
  • OptiNose, Inc. OptiNose develops and commercializes drug-device combinations based on its proprietary nasal delivery technology (e.g., Xhance). It is a directly comparable technology platform for nasal drug delivery that informs device-formulation strategy for Enbumyst-style products.

Direct peers

  • scPharmaceuticals Inc. scPharmaceuticals developed Furoscix, a subcutaneous furosemide on-body infusor for outpatient heart failure decongestion. It is the most direct competitive comparable to Corstasis' outpatient diuretic strategy and serves the same CHF fluid-overload patient population through a similar self-administered approach.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Corstasis Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Corstasis Therapeutics leadership team

Management profile

Number of profiles

Profiles3 records

Corstasis Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Corstasis Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Corstasis Therapeutics

What does Corstasis Therapeutics do?

Corstasis Therapeutics is a commercial-stage biopharmaceutical company that develops and commercializes nasal and subcutaneous formulations of loop diuretics. Its core offering is Enbumyst (bumetanide nasal spray) 0.5 mg, the first FDA-approved nasal spray loop diuretic for outpatient treatment of fluid overload associated with congestive heart failure, liver disease, and kidney disease. The company also has a pipeline of investigational subcutaneous and veterinary diuretic delivery programs.

Is Corstasis Therapeutics a public or private company?

Corstasis Therapeutics is a private company. It is classified as venture growth investor backed and is currently acquired.

When was Corstasis Therapeutics founded?

Corstasis Therapeutics was founded in 2023. It employs 1 to 10 people.

Where is Corstasis Therapeutics based?

Corstasis Therapeutics is headquartered in Henderson, United States, in the North America region.

How does Corstasis Therapeutics make money?

Two revenue lines are on record. Enbumyst product sales are the primary driver. The others are milestone payments from acquisition.

Who are Corstasis Therapeutics's main competitors?

Broad incumbents on record are American Regent, Pfizer Inc., Eli Lilly and Company and Esperion Therapeutics. Emerging players are Cytokinetics, Inc., Impel Pharmaceuticals, Windtree Therapeutics, BioCardia, Inc. and OptiNose, Inc.. scPharmaceuticals Inc. is listed as a direct peer.

Does Corstasis Therapeutics have an API?

No public API is recorded for Corstasis Therapeutics.

What industry is Corstasis Therapeutics in?

Corstasis Therapeutics's product category is Cardiovascular Pharmaceuticals. Its primary akta.pro industry code is HLAHAIAK, Nasal Drug Delivery Devices (Sprays/Powder Devices). Its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireEsperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)Esperion Therapeutics closed its acquisition of Corstasis Therapeutics, gaining Enbumyst, the first FDA-approved nasal spray loop diuretic for edema in heart failure and hepatic/renal disease. The product received FDA approval in September 2025, and Esperion plans to leverage its cardiovascular commercial infrastructure to drive adoption and revenue growth.Investing.comEsperion sells Japan royalty rights for $50 million to Athyrium By Investing.comEsperion Therapeutics Inc. announced that Athyrium Capital Management purchased royalties from Japan sales of Otsuka Pharmaceutical's bempedoic acid products for $50 million. The proceeds will support Esperion’s acquisition of Corstasis Therapeutics Inc., a company that developed the FDA-approved Enbumyst nasal spray.GlobeNewswireAthyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis TherapeuticsAthyrium Capital Management has entered into a $50 million royalty financing agreement with Esperion Therapeutics, acquiring 100% of Esperion's royalty interest on Otsuka's bempedoic acid product net sales in Japan from January 1, 2026, along with related milestone payments. Under the terms, Athyrium Funds will receive tiered royalties ranging from 12% to 33% until aggregate payments reach 2.0x their investment, after which rights revert to Esperion. The financing is specifically designed to support Esperion's acquisition of Corstasis Therapeutics, whose lead asset Enbumyst is the first FDA-approved intranasal loop diuretic.YahooAthyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis TherapeuticsAthyrium Capital Management and Esperion Therapeutics entered into a $50 million royalty financing agreement under which Athyrium Funds acquired 100% of Esperion's royalty interest on Otsuka's bempedoic acid products in Japan, with tiered royalties ranging from 12% to 33% until aggregate payments reach 2.0x their investment. The financing provides Esperion with non-dilutive capital to support its acquisition of Corstasis Therapeutics, a commercial-stage cardiovascular company whose lead product Enbumyst is the first FDA-approved intranasal loop diuretic for treating edema associated with cardiovascular, hepatic, and renal disease.GurufocusEsperion (ESPR) Secures $50M Royalty Financing Deal with AthyriuEsperion (ESPR) has secured a $50 million royalty financing agreement with Athyrium Capital Management, under which Athyrium will acquire Esperion's royalty interest on Otsuka Pharmaceutical's net sales of bempedoic acid products in Japan. The non-dilutive capital will fund Esperion's acquisition of Corstasis Therapeutics, a commercial-stage cardiovascular firm offering Enbumyst, the only FDA-approved intranasal loop diuretic for edema related to cardiovascular, hepatic, and renal conditions. This marks Athyrium's second major financial collaboration with Esperion in 16 months, following a previous $150 million senior secured loan facility.MarketScreenerAthyrium Capital Management and Esperion enter into $50 million Japan royalty financing to support strategic acquisition of Corstasis TherapeuticsAthyrium Capital Management and Esperion Therapeutics have entered into a $50 million Japan royalty financing agreement to fund Esperion's strategic acquisition of Corstasis Therapeutics. The transaction provides Esperion with capital in exchange for royalty rights tied to its Japan operations or assets. This financing structure enables Esperion to pursue growth through M&A while securing non-dilutive capital for the deal.GlobeNewswireEsperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateEsperion reported Q4 2025 total revenue of $168.4 million, up 144% year-over-year, and full-year revenue of $403.1 million, up 21%. U.S. net product revenue grew 38% to $159.6 million, and the company agreed to acquire Corstasis Therapeutics to expand its cardiovascular franchise. It expects 2026 operating expenses of $225–255 million.Pulse 2.0Esperion Therapeutics: $75 Million Acquisition Of Corstasis To Expand Cardiovascular Franchise With Enbumyst Nasal SprayEsperion Therapeutics has agreed to acquire Corstasis Therapeutics, a commercial-stage biopharmaceutical company, for $75 million upfront plus up to $180 million in potential milestone payments and low double-digit royalties on worldwide sales. The acquisition brings Enbumyst (bumetanide nasal spray), the first and only FDA-approved nasal spray loop diuretic for edema associated with congestive heart failure, into Esperion's cardiovascular portfolio. The deal, expected to close in Q2 2026, will be financed through existing credit facilities and royalty monetization, with Esperion targeting the approximately 6.7 million U.S. adults living with congestive heart failure as the primary patient population.